Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
BioVie to Present at ThinkEquity Conference in NYC on May 2nd | ||
By: Nasdaq / GlobeNewswire - 24 Apr 2019 | Back to overview list |
|
LOS ANGELES, April 24, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced that Mr. Terren Peizer, the Company’s Chairman and CEO, is scheduled to participate in the ThinkEquity Conference on May 2, 2019 in New York City. This event is dedicated to connecting small and micro-cap companies with high-level institutional and retail investors. Management will hold one-on-one meetings with investors during the conference. Event details: BioVie will present a company overview and clinical trial update on Thursday, May 2, 2019 at the Mandarin Oriental Hotel in New York City at 2:00 pm Eastern Time. Following the event, a copy of the presentation will be available in the Investors section of the Company's website at: About BioVie BIV201 (continuous infusion terlipressin) is being investigated as a potential new therapy for patients suffering from ascites, hepatorenal syndrome (HRS), and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. The initial disease target for BIV201 therapy is ascites, which is a serious complication of advanced liver cirrhosis. The FDA has never approved any drug specifically for treating ascites. The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis, but is not available in the US or Japan. BIV201 has received Orphan Drug designations for the treatment of ascites and for HRS, has FDA Fast Track status, and US patent protection. For more information about BioVie, please visit our website: www.biovieinc.com. Forward-Looking Statements CONTACT INFORMATION |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |